There are currently 179 clinical trials in Toledo, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Toledo, Toledo Hospital, Toledo Clinic Cancer Centers-Toledo and ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or II
Recruiting
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
03/07/2025
Locations: KalVista Investigative Site, Toledo, Ohio
Conditions: Hereditary Angioedema
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Recruiting
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: The Toledo Clinic Cancer Center, Toledo, Ohio
Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Recruiting
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Toledo Medical Center ( Site 4002), Toledo, Ohio
Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
Recruiting
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Research Site, Toledo, Ohio
Conditions: Post-Operative Complications in Cardiac Surgery
Patient Retrospective Outcomes (PRO)
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Interventional Pain Consultants, Toledo, Ohio +2 locations
Conditions: Chronic Pain
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2025
Locations: ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio
Conditions: Glioblastoma, Gliosarcoma
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Recruiting
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2025
Locations: Mercy Health - St. Vincent Medical Center, Toledo, Ohio +1 locations
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of Toledo Medical Center, Toledo, Ohio
Conditions: Focal Onset Seizures
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Recruiting
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Gender:
ALL
Ages:
17 years and below
Trial Updated:
02/27/2025
Locations: Toledo Children's Hospital, Toledo, Ohio
Conditions: Bacterial Infections
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
Recruiting
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients \<18 years old with a confirmed or suspected bacterial infection.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/27/2025
Locations: Toledo Children's Hospital, Toledo, Ohio
Conditions: Gram Positive Bacterial Infections
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
Recruiting
The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
02/24/2025
Locations: ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center, Toledo, Ohio
Conditions: Cystic Fibrosis